Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
Abnormal Proliferation02:23

Abnormal Proliferation

4.9K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.9K
General Transcription Factors01:30

General Transcription Factors

6.3K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
6.3K
Tumor Immunotherapy01:27

Tumor Immunotherapy

880
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
880
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.4K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.4K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
このページは機械翻訳されています。他のページは英語で表示される場合があります。View in English
  1. ホーム
  2. 研究分野
  3. 生物医学と臨床科学
  4. 腫瘍学とがん発生
  5. 分子標的
  6. Nr4a転写因子は,固体腫瘍におけるcar T細胞機能を制限する.

NR4A転写因子は,固体腫瘍におけるCAR T細胞機能を制限する.

Joyce Chen1,2,3,4, Isaac F López-Moyado5,6,7, Hyungseok Seo5

  • 1Division of Signaling and Gene Expression, La Jolla Institute for Immunology, La Jolla, CA, USA. jchen@lji.org.

Nature
|March 1, 2019

関連する実験動画

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.2K

PubMed で要約を見る

まとめ
この要約は機械生成です。

固体腫瘍を標的とするキメリック抗原受容体 (CAR) T細胞は,NR4A転写因子により機能不全する. これらのNR4A因子を抑制することで,CAR T細胞の機能を回復させ,がんの免疫療法を改善することができます.

科学分野:

  • 免疫学
  • 癌 生物学
  • 分子生物学

背景:

  • 化学抗原受容体 (CAR) T細胞は,B細胞の悪性腫瘍に対して有効だが,固体腫瘍に対してはそれほど有効ではない.
  • 固体腫瘍におけるCAR T細胞機能障害は,慢性的な抗原刺激と抑制受容体のアップレギュレーションに関連しています.
  • この低反応状態は,特異的な転写因子活性化経路を伴う.

研究 の 目的:

  • 固体腫瘍におけるCAR T細胞の反応低下のメカニズムを調査する.
  • CAR T細胞の機能障害に関与する重要な分子要素を特定する.
  • 癌の免疫療法におけるCAR T細胞の有効性を高めるための新しい治療目標を探求する.

主な方法:

  • ヒトのCD19反応性CAR T細胞をCD19+腫瘍を持つマウスモデルに移植する.
  • 腫瘍浸透性リンパ球 (TIL) の遺伝子発現とクロマチンアクセシビリティの分析.
  • NR4A転写因子トリプルノックアウトCAR T細胞の生成と評価

主要な成果:

  • 腫瘍におけるCD8+ CAR T細胞と内生TIL細胞は,NR4A転写因子に関連した類似した遺伝子発現プロファイルを示した.
  • NR4A転写因子は,がん患者および慢性感染症患者からのT細胞で高く表現されました.

関連する実験動画

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.0K
Generation of Human Chimeric Antigen Receptor Regulatory T Cells
10:29

Generation of Human Chimeric Antigen Receptor Regulatory T Cells

Published on: January 3, 2025

2.0K
Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy
09:12

Author Spotlight: Advancements in Hypoxia-Sensitive CAR-T Therapy for Enhanced Cancer Immunotherapy

Published on: June 14, 2024

1.2K
  • NR4AトリプルノックアウトCAR T細胞は腫瘍の回帰を促進し,生存期間を延長し,エフェクターT細胞のフェノタイプを示した.
  • 結論:

    • NR4A転写因子は,T細胞の過反応性において,細胞内にある重要な役割を果たします.
    • NR4A抑制は,がんにおけるCAR T細胞機能障害を克服するための有望な戦略です.
    • NR4A因子をターゲットにすることで,固体腫瘍に対するCAR T細胞治療の有効性が向上する可能性があります.